Related references
Note: Only part of the references are listed.Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Paolo A. A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Digital pathology and artificial intelligence in translational medicine and clinical practice
Vipul Baxi et al.
MODERN PATHOLOGY (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Byoung Chul Cho et al.
LANCET ONCOLOGY (2022)
Inducible de novo expression of neoantigens in tumor cells and mice
Martina Damo et al.
NATURE BIOTECHNOLOGY (2021)
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
Mark M. Awad et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M. Regan et al.
CLINICAL CANCER RESEARCH (2021)
DREAMseq (Doublet Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial-ECOG-ACRIN EA6134
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Drug-Dosing Conundrum in Oncology - When Less Is More
Mirat Shah et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biomarker Discovery and Validation: Statistical Considerations
Fang-Shu Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma
Simon Chowdhury et al.
CLINICAL GENITOURINARY CANCER (2021)
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
Geoffrey T. Gibney et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment
Andrew G. Robinson et al.
JOURNAL OF CANCER POLICY (2021)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Thomas Powles et al.
NATURE (2021)
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ
Sanjay Chandrasekaran et al.
FRONTIERS IN IMMUNOLOGY (2021)
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Aaron C. Tan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy
Frank J. Borm et al.
CANCERS (2021)
Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis
Khader Shameer et al.
FRONTIERS IN ONCOLOGY (2021)
Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
Mithunah Krishnamoorthy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Key indicators of phase transition for clinical trials through machine learning
Felipe Feijoo et al.
DRUG DISCOVERY TODAY (2020)
Monitoring CD8a+ T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [64Cu]NOTA-CD8a PET Imaging
Lotte K. Kristensen et al.
MOLECULAR IMAGING AND BIOLOGY (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells
Jason B. Williams et al.
NATURE COMMUNICATIONS (2020)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M. Kluger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Luca Mazzarella et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
Cornelis M. van Tilburg et al.
BMC CANCER (2020)
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
Nikhil Khushalani et al.
FUTURE ONCOLOGY (2020)
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
Nicolas Epaillard et al.
BULLETIN DU CANCER (2020)
Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
P. Nathan et al.
ANNALS OF ONCOLOGY (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153
David M. Waterhouse et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman et al.
NATURE CANCER (2020)
Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials
Emmett V. Schmidt et al.
JAMA NETWORK OPEN (2020)
Estimation of clinical trial success rates and related parameters
Chi Heem Wong et al.
BIOSTATISTICS (2019)
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Brian C. Miller et al.
NATURE IMMUNOLOGY (2019)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
Sonja Althammer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses
Ismail M. Meraz et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade
Stefan Zimmermann et al.
JAMA ONCOLOGY (2019)
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma
Meredith M. Regan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology
Kaustav Bera et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions
Rick A. Vreman et al.
VALUE IN HEALTH (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
K. M. Heinhuis et al.
ANNALS OF ONCOLOGY (2019)
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
Jonathan A. Trujillo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
Association between progression-free survival and patients' quality of life in cancer clinical trials
Thomas J. Hwang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Value and Values in Cancer Care. Assessing the Benefit of Treatment in Patients with Advanced Cancer
Jan Schildmann
ONCOLOGY RESEARCH AND TREATMENT (2019)
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study
Nicholas R. Latimer et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2018)
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
Ariadna Tibau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
Ariadna Tibau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review
Reyad Dada
ANNALS OF HEMATOLOGY (2018)
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T. R. Cottrell et al.
ANNALS OF ONCOLOGY (2018)
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Vancheswaran Gopalakrishnan et al.
CANCER CELL (2018)
Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
Etienne Giroux Leprieur et al.
ONCOIMMUNOLOGY (2018)
Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies
Qiang Wang et al.
CANCER LETTERS (2018)
A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab
David Fabrizio et al.
CANCER RESEARCH (2018)
Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616)
Ari M. Vanderwalde et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Marvin Kuske et al.
PHARMACOLOGICAL RESEARCH (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016
Thomas J. Moore et al.
JAMA INTERNAL MEDICINE (2018)
CAR T Cells in Solid Tumors: Blueprints for Building effective Therapies
Hannah M. Knochelmann et al.
FRONTIERS IN IMMUNOLOGY (2018)
Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology A Systematic Review and Quantitative Analysis
Bruno Kovic et al.
JAMA INTERNAL MEDICINE (2018)
Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review
David B. Fogel
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2018)
Where does PD-1 blockade fit in HL therapy?
Alex F. Herrera
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
J. C. Del Paggio et al.
ANNALS OF ONCOLOGY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
What constitutes an unmet medical need in oncology? An empirical evaluation of author usage in the biomedical literature
Eric Lu et al.
SEMINARS IN ONCOLOGY (2017)
Landmark cure rate models with time-dependent covariates
Haolun Shi et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2017)
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
Irene Scarfo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer
Andrew Zloza et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Combination immunotherapy: a road map
Patrick A. Ott et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method
Nicholas R. Latimer et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2017)
Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis
Sami Blom et al.
SCIENTIFIC REPORTS (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review
Denis L. Jardim et al.
CANCER TREATMENT REVIEWS (2017)
Predicting analysis times in randomized clinical trials with cancer immunotherapy
Tai-Tsang Chen
BMC MEDICAL RESEARCH METHODOLOGY (2016)
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
Elham Beyranvand Nejad et al.
CANCER RESEARCH (2016)
Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap
J. Jason Morton et al.
CANCER RESEARCH (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im et al.
NATURE (2016)
Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma
David G. McFadden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Value Based Care and Patient-Centered Care: Divergent or Complementary?
Eric K. Tseng et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Canine cancer immunotherapy studies: linking mouse and human
Jiwon S. Park et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Immuno-oncology combinations: raising the tail of the survival curve
Sarnuel J. Harris et al.
CANCER BIOLOGY & MEDICINE (2016)
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen
Rebecca A. Evans et al.
JCI INSIGHT (2016)
A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds
J. A. DiMasi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact analysis of ICH S9 on non-clinical development of anticancer drugs
Milton Bonelli et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2015)
Treatment switching in oncology trials and the acceptability of adjustment methods
Nicholas R. Latimer
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2015)
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Tai-Tsang Chen
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
Rosemarie Mick et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Pharmaceutical R&D Performance by Firm Size: Approval Success Rates and Economic Returns
Joseph A. DiMasi
AMERICAN JOURNAL OF THERAPEUTICS (2014)
Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012
Leonard V. Sacks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Statistical issues and challenges in immuno-oncology
Tai-Tsang Chen
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
How valid are claims for synergy in published clinical studies?
A. Ocana et al.
ANNALS OF ONCOLOGY (2012)
Randomized Phase II Trial Designs With Biomarkers
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Randomized Phase II Trials: A Long-term Investment With Promising Returns
Manish R. Sharma et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Optimising the design of phase II oncology trials: The importance of randomisation
Mark J. Ratain et al.
EUROPEAN JOURNAL OF CANCER (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trials published in 2002: A cross-specialty comparison showing significant design differences between oncology trials and other medical specialties
Laura C. Michaelis et al.
CLINICAL CANCER RESEARCH (2007)
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank et al.
CANCER RESEARCH (2004)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
